Abstract
3-Iodo-6-methoxybenzamide (123I-IBZM), a new Dopamine D2 receptor ligand, was used in conjunction with SME 810 brain tomography to study six subjects (one normal volunteer, four schizophrenics and one DAT patient). Initial Dynamic SPET was followed by multislice SPET. High-resolution images of the D2 receptor distribution in the basal ganglia were obtained. The specific binding in D2 receptors of the basal ganglia is highest from 2–4 h p.i. Patients on anti-psychotic drugs showed significantly lower specific binding. Dopamine D2 brain receptor availability in man may now be studied with SPET. Continuous data acquisition with single slice tomography is particularly important in the study of this type of radiotracers.
This is a preview of subscription content, log in via an institution to check access.
References
Alavi A, Velchik MG, Kung HF, Kung MP, Chang W, Noto R, Pan S, Billings J, Sorgentoni K, Rauch A, Reilley J (1989) Imaging of the basal ganglia in the human brain with I-123-IBZM: a new CNS D2 receptor agent. J Nucl Med 30(5):731
Kung HF, Pan S, Kung MP, Billings J, Kasliwal R, Reilley J, Alavi A (1989) In vitro and in vivo evaluation of [123I]IBZM: a potential CNS D-2 dopamine receptor imaging agent. J Nucl Med 30(1):88–92
Verhoeff NPLG, Bobeldijk M, Van Royen EA, Feenstra MGP, Boer GJ, Van Dorremalen P (1989) In vitro and in vivo binding of dopamine D2-receptors with123I-iodobenzamide in rat brain. Pharm Weekbl [Sci] 11 (Suppl J):113
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Costa, D.C., Verhoeff, N.P.L.G., Cullum, I.D. et al. In vivo characterisation of 3-iodo-6-methoxybenzamide123I in humans. Eur J Nucl Med 16, 813–816 (1990). https://doi.org/10.1007/BF00833017
Issue Date:
DOI: https://doi.org/10.1007/BF00833017